Fairmount Funds Management

Fairmount Funds Management LLC is an active institutional investor focused on supporting innovative biotechnology and life science companies developing differentiated therapeutics. The firm manages over $1 billion in assets and has invested in numerous public and private biotech firms across various therapeutic areas. It does not develop drugs or technologies itself but provides strategic capital to enable clinical development by its portfolio companies. Recent investments include significant positions in Axsome Therapeutics (CNS), Apogee Therapeutics (immunology/inflammation), Spyre Therapeutics (antibody therapeutics for IBD), Enliven Therapeutics (oncology), Nuvalent (oncology/precision medicine), Oruka Therapeutics, among others. The company’s investment activity spans early-stage through late-stage clinical programs. No direct clinical results are attributable to the fund itself. Pipeline breadth and details pertain to its investees rather than the fund.